Genkyotex Stock LIQUIDNET SYSTEMS

Stocks

FR0011790542

Biotechnology & Medical Research

End-of-day quote LIQUIDNET SYSTEMS 5-day change 1st Jan Change
- EUR -.--% Intraday chart for Genkyotex -.--% -
Director TitleAgeSince
Chairman 53 2022-01-20
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 52.02M
+1.70%+6.89%+2.76%+7.65% 49.15B
+0.92%+6.21%+408.85%+607.44% 40.23B
+1.89%+11.06%+25.75%-7.89% 34.55B
+2.38%+8.10%+21.83%+66.94% 33.09B
+3.96%+6.07%+14.14%+37.68% 25.19B
+2.51%+4.94% - - 17.05B
+2.58%+7.24%+71.03%+132.17% 15.92B
+0.32%+1.58%+14.34%+19.26% 13.83B
-1.14%+7.52%+14.75%-30.83% 13.26B
Average +1.51%+5.99%+71.68%+104.05% 26.92B
Weighted average by Cap. +1.81%+6.31%+89.14%+131.73%
Logo Genkyotex
GenKyoTex SA is a France-based company involved in the biotechnology sector. The Company focuses on the development of therapies based on selective inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NOX) enzymes, which cause a range of disease processes, such as fibrosis, inflammation, pain processing, cancer development and neurodegeneration. The Company's pipeline includes GKT831, a NOX inhibitor aimed at primary biliary cholangitis (PBC) and fibrosis; GKT771, a NOX inhibitor mainly aimed at inflammatory pain and angiogenesis, and other NOX inhibitors, which target at central nervous system (CNS), hearing loss and oncology.
Employees
-